CL2007003614A1 - Compuestos derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona; composicion farmaceutica que comprende a dicho compuesto; procedimiento de preparacion; y uso del compuesto en el tratamiento de trastornos del metabolismo, como diabetes mellitus, dis - Google Patents

Compuestos derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona; composicion farmaceutica que comprende a dicho compuesto; procedimiento de preparacion; y uso del compuesto en el tratamiento de trastornos del metabolismo, como diabetes mellitus, dis

Info

Publication number: CL2007003614A1
Authority: CL; Chile
Prior art keywords: compound; sulfonil; fenil; ona; oxadiazol
Prior art date: 2006-12-14

Application number

CL200703614A

Other languages

English (en)

Inventor

Stefanie Urmann Matthias Keil

Original Assignee

Sanofi Aventis

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-12-14

Filing date

2007-12-12

Publication date

2008-06-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37998695&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2007003614(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-12-12 Application filed by Sanofi Aventis filed Critical Sanofi Aventis

2008-06-20 Publication of CL2007003614A1 publication Critical patent/CL2007003614A1/es

Links

150000001875 compounds Chemical class 0.000 title 3
206010012601 diabetes mellitus Diseases 0.000 title 1
208000030159 metabolic disease Diseases 0.000 title 1
238000000034 method Methods 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Dermatology (AREA)
Cardiology (AREA)
Hematology (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Physical Education & Sports Medicine (AREA)
Oncology (AREA)
Emergency Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychology (AREA)
Psychiatry (AREA)
Communicable Diseases (AREA)
Toxicology (AREA)

CL200703614A 2006-12-14 2007-12-12 Compuestos derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona; composicion farmaceutica que comprende a dicho compuesto; procedimiento de preparacion; y uso del compuesto en el tratamiento de trastornos del metabolismo, como diabetes mellitus, dis CL2007003614A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP06025880A EP1932843A1 (en)	2006-12-14	2006-12-14	Sulfonyl-phenyl-2H-(1,2,4) oxadiazole-5-one derivatives, processes for their preparation and their use as pharmaceuticals

Publications (1)

Publication Number	Publication Date
CL2007003614A1 true CL2007003614A1 (es)	2008-06-20

Family

ID=37998695

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL200703614A CL2007003614A1 (es)	2006-12-14	2007-12-12	Compuestos derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona; composicion farmaceutica que comprende a dicho compuesto; procedimiento de preparacion; y uso del compuesto en el tratamiento de trastornos del metabolismo, como diabetes mellitus, dis

Country Status (24)

Country	Link
US (1)	US8173674B2 (es)
EP (2)	EP1932843A1 (es)
JP (1)	JP2010512352A (es)
KR (1)	KR20090087922A (es)
CN (1)	CN101558064A (es)
AR (1)	AR064299A1 (es)
AU (1)	AU2007331805A1 (es)
BR (1)	BRPI0720416A2 (es)
CA (1)	CA2672347A1 (es)
CL (1)	CL2007003614A1 (es)
CO (1)	CO6210729A2 (es)
CR (1)	CR10778A (es)
EC (1)	ECSP099409A (es)
MA (1)	MA30981B1 (es)
MX (1)	MX2009005535A (es)
NO (1)	NO20092293L (es)
PE (1)	PE20081404A1 (es)
RU (1)	RU2009126745A (es)
SV (1)	SV2009003293A (es)
TN (1)	TN2009000242A1 (es)
TW (1)	TW200843749A (es)
UY (1)	UY30783A1 (es)
WO (1)	WO2008071311A1 (es)
ZA (1)	ZA200903160B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8716317B2 (en) *	2008-06-09	2014-05-06	Sanofi	Sulfonamides with heterocycle and oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
US8329725B2 (en)	2008-06-09	2012-12-11	Sanofi	Annelated pyrrolidin sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
WO2011107494A1 (de)	2010-03-03	2011-09-09	Sanofi	Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011157827A1 (de)	2010-06-18	2011-12-22	Sanofi	Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en)	2010-06-21	2013-09-10	Sanofi	Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2013037390A1 (en)	2011-09-12	2013-03-21	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en)	2011-09-27	2015-10-21	Sanofi	6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8859774B2 (en)	2012-05-25	2014-10-14	Corcept Therapeutics, Inc.	Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US12226412B2 (en)	2012-05-25	2025-02-18	Corcept Therapeutics, Inc.	Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
CA2872260C (en) *	2012-05-25	2020-12-22	Corcept Therapeutics, Inc.	Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
WO2017076757A1 (en)	2015-11-02	2017-05-11	Basf Se	Substituted oxadiazoles for combating phytopathogenic fungi
EP3165094A1 (en)	2015-11-03	2017-05-10	Basf Se	Substituted oxadiazoles for combating phytopathogenic fungi
US20180317490A1 (en)	2015-11-04	2018-11-08	Basf Se	Substituted oxadiazoles for combating phytopathogenic fungi
MX2018006235A (es)	2015-11-19	2018-08-01	Basf Se	Oxadiazoles sustituidos para combatir hongos fitopatogenos.
EA201891146A1 (ru)	2015-11-19	2018-12-28	Басф Се	Замещенные оксадиазолы для борьбы с фитопатогенными грибами
AU2017250397A1 (en)	2016-04-11	2018-10-11	Basf Se	Substituted oxadiazoles for combating phytopathogenic fungi
BR112018074559A2 (pt)	2016-06-09	2019-03-12	Basf Se	compostos, composição agroquímica, uso de compostos e método para combater fungos nocivos fitopatogênicos
BR112018074569B1 (pt)	2016-06-09	2022-10-04	Basf Se	Compostos, uso de n-(2,4-difluorofenil)-4-[5-(trifluorometil)-1,2,4-oxadiazol-3-il] benzamida, composição agroquímica e método para combater fungos nocivos fitopatogênicos
WO2018114393A1 (en)	2016-12-19	2018-06-28	Basf Se	Substituted oxadiazoles for combating phytopathogenic fungi
EP3339297A1 (en)	2016-12-20	2018-06-27	Basf Se	Substituted oxadiazoles for combating phytopathogenic fungi
MX2019011543A (es)	2017-03-31	2019-12-16	Corcept Therapeutics Inc	Moduladores del receptor de glucocorticoides para el tratamiento de cancer cervical.
WO2018219797A1 (en)	2017-06-02	2018-12-06	Basf Se	Substituted oxadiazoles for combating phytopathogenic fungi
WO2018234139A1 (en)	2017-06-19	2018-12-27	Basf Se	2-[[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]aryloxy](thio)acetamides for combating phytopathogenic fungi
WO2019002158A1 (en)	2017-06-30	2019-01-03	Basf Se	SUBSTITUTED TRIFLUOROMETHYLOXADIAZOLES FOR THE CONTROL OF PHYTOPATHOGENIC FUNGI
US11076596B2 (en)	2017-09-18	2021-08-03	Basf Se	Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi
WO2019101511A1 (en)	2017-11-23	2019-05-31	Basf Se	Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi
US11234971B2 (en)	2018-12-19	2022-02-01	Corcept Therapeutics Incorporated	Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
US11389432B2 (en)	2018-12-19	2022-07-19	Corcept Therapeutics Incorporated	Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
US11464764B2 (en)	2018-12-19	2022-10-11	Corcept Therapeutics Incorporated	Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound
JP7789561B2 (ja)	2019-02-22	2025-12-22	コーセプトセラピューティクス，インコーポレイテッド	レラコリラント、ヘテロアリール－ケトン縮合アザデカリングルココルチコイド受容体調節物質の治療用途
CN115361866B (zh) *	2020-03-31	2025-07-18	株式会社Lg化学	用于保护胰岛移植的组合物
WO2021242912A1 (en)	2020-05-27	2021-12-02	Corcept Therapeutics Incorporated	Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of cyp2c8 and cyp3a4
WO2022134033A1 (en)	2020-12-25	2022-06-30	Corcept Therapeutics Incorporated	Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
KR20250073629A (ko)	2022-10-06	2025-05-27	코어셉트 쎄라퓨틱스 인코포레이티드	글루코코르티코이드 수용체 조절제의 제형
US12433882B2 (en)	2022-10-28	2025-10-07	Corcept Therapeutics Incorporated	Treatments for amyotrophic lateral sclerosis using dazucorilant

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5641796A (en) *	1994-11-01	1997-06-24	Eli Lilly And Company	Oral hypoglycemic agents
DE10222034A1 (de) *	2002-05-17	2003-11-27	Bayer Ag	Tetrahydroisochinolin-Derivate
DE10229777A1 (de) *	2002-07-03	2004-01-29	Bayer Ag	Indolin-Phenylsulfonamid-Derivate
JPWO2004080943A1 (ja) *	2003-03-11	2006-06-08	小野薬品工業株式会社	シンナミルアルコール誘導体化合物およびその化合物を有効成分として含有する薬剤
CA2521175A1 (en)	2003-04-07	2004-10-28	Kalypsys, Inc.	Para-sulfonyl substituted phenyl compounds as modulators of ppars
DE10335449A1 (de)	2003-08-02	2005-02-17	Bayer Healthcare Ag	Bicyclische Indolinsulfonamid-Derivate
EP1586573B1 (en) *	2004-04-01	2007-02-07	Sanofi-Aventis Deutschland GmbH	Oxadiazolones, processes for their preparation and their use as pharmaceuticals

2006
- 2006-12-14 EP EP06025880A patent/EP1932843A1/en not_active Withdrawn
2007
- 2007-11-30 JP JP2009540626A patent/JP2010512352A/ja not_active Abandoned
- 2007-11-30 AU AU2007331805A patent/AU2007331805A1/en not_active Abandoned
- 2007-11-30 CN CNA2007800454445A patent/CN101558064A/zh active Pending
- 2007-11-30 KR KR1020097012309A patent/KR20090087922A/ko not_active Withdrawn
- 2007-11-30 MX MX2009005535A patent/MX2009005535A/es not_active Application Discontinuation
- 2007-11-30 EP EP07846915.2A patent/EP2102198B1/en active Active
- 2007-11-30 RU RU2009126745/04A patent/RU2009126745A/ru not_active Application Discontinuation
- 2007-11-30 BR BRPI0720416-7A patent/BRPI0720416A2/pt not_active IP Right Cessation
- 2007-11-30 WO PCT/EP2007/010390 patent/WO2008071311A1/en not_active Ceased
- 2007-11-30 CA CA002672347A patent/CA2672347A1/en not_active Abandoned
- 2007-12-12 TW TW096147333A patent/TW200843749A/zh unknown
- 2007-12-12 AR ARP070105563A patent/AR064299A1/es not_active Application Discontinuation
- 2007-12-12 UY UY30783A patent/UY30783A1/es not_active Application Discontinuation
- 2007-12-12 CL CL200703614A patent/CL2007003614A1/es unknown
- 2007-12-12 PE PE2007001772A patent/PE20081404A1/es not_active Application Discontinuation
2009
- 2009-05-07 ZA ZA200903160A patent/ZA200903160B/xx unknown
- 2009-05-07 CR CR10778A patent/CR10778A/es not_active Application Discontinuation
- 2009-06-05 CO CO09058528A patent/CO6210729A2/es not_active Application Discontinuation
- 2009-06-09 US US12/480,974 patent/US8173674B2/en not_active Expired - Fee Related
- 2009-06-10 SV SV2009003293A patent/SV2009003293A/es unknown
- 2009-06-10 MA MA31971A patent/MA30981B1/fr unknown
- 2009-06-12 TN TNP2009000242A patent/TN2009000242A1/fr unknown
- 2009-06-12 EC EC2009009409A patent/ECSP099409A/es unknown
- 2009-06-15 NO NO20092293A patent/NO20092293L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
AU2007331805A1 (en)	2008-06-19
TW200843749A (en)	2008-11-16
ECSP099409A (es)	2009-07-31
WO2008071311A1 (en)	2008-06-19
CN101558064A (zh)	2009-10-14
ZA200903160B (en)	2010-10-27
CO6210729A2 (es)	2010-10-20
PE20081404A1 (es)	2008-11-04
NO20092293L (no)	2009-09-08
JP2010512352A (ja)	2010-04-22
CA2672347A1 (en)	2008-06-19
AR064299A1 (es)	2009-03-25
EP1932843A1 (en)	2008-06-18
EP2102198B1 (en)	2015-02-25
CR10778A (es)	2009-06-24
RU2009126745A (ru)	2011-01-20
TN2009000242A1 (en)	2010-10-18
EP2102198A1 (en)	2009-09-23
MX2009005535A (es)	2009-06-05
US20090298871A1 (en)	2009-12-03
SV2009003293A (es)	2009-10-27
MA30981B1 (fr)	2009-12-01
UY30783A1 (es)	2008-07-31
US8173674B2 (en)	2012-05-08
BRPI0720416A2 (pt)	2013-12-31
KR20090087922A (ko)	2009-08-18

Similar Documents

Publication	Publication Date	Title
CL2007003614A1 (es)	2008-06-20	Compuestos derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona; composicion farmaceutica que comprende a dicho compuesto; procedimiento de preparacion; y uso del compuesto en el tratamiento de trastornos del metabolismo, como diabetes mellitus, dis
CL2007003033A1 (es)	2008-05-16	Compuestos derivados de benzoilamino heterociclos; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la diabetes tipo ii.
CL2007002197A1 (es)	2008-02-15	Compuestos derivados de indol; procedimiento de preparacion; compuesto intermediario; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes mellitus, retinopatia diabetica, hiperglucemia, hiperl
CL2006003672A1 (es)	2008-02-08	Compuestos derivados de pirimido-[4,5-b]-oxazinas; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de diabetes mellitus y/u obesidad.
CL2007002121A1 (es)	2008-02-22	Compuestos derivados de pirazoles, activadores de glucoquinasa; proceso de preparacion de dichos compuestos; composicion farmaceutica que comprende dichos compuestos; y uso para el tratamiento de enfermedades y/o trastornos metabolicos, tal como diab
CL2008000133A1 (es)	2008-05-23	Composicion farmaceutica que comprende un compuesto derivado de pirazol-o-glucosido combinado con al menos un segundo agente terapeutico; y uso de la composicion para el tratamiento de diabetes mellitus, cataratas, neuropatia, infarto de miocardio, e
CL2008003116A1 (es)	2010-02-05	Compuestos heterocíclicos bicíclicos; composición farmacéutica que comprende a dichos compuestos; y su uso en el tratamiento o prevención de enfermedades tales como diabetes, obesidad, trastorno metabólico, enfermedad cardiovascular entre otras.
CL2007001992A1 (es)	2008-07-18	Compuestos derivados de pirimidilciclopentanos; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de una enfermedad inflamatoria, hiperproliferante, cardiovascular, neurodege
CL2008000255A1 (es)	2008-08-08	Compuestos derivados de 2-aminooxazolinas; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de la depresion, ansiedad, trastorno bipolar, esquizofrenia, parkinson, alzheimer
CL2007003244A1 (es)	2008-04-04	Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
CL2007003440A1 (es)	2008-04-04	Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9 desaturasa; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, resistencia a la insulina, trastornos de lipidos, obesida
CL2008003593A1 (es)	2010-01-04	Compuestos derivados de isoxazolo-piridazina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de trastornos cognitivos como el alzheimer
CL2007003202A1 (es)	2008-03-07	Compuestos derivados de espiroindolinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos de proliferacion celular.
CL2007002610A1 (es)	2008-02-01	Compuestos derivados de bipiridina sustituida; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o la profilaxis de enfermedades tales como hipertonia, diabetes, infarto de miocardio, entre otras.
CL2008001125A1 (es)	2008-10-24	Compuestos derivados de pirimidinona condensada con heterociclos; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, sindrome metabolico y obesidad.
CL2007003262A1 (es)	2008-05-30	Compuestos derivados de 1,4-benzotiepina-1,1-dioxido; composicion farmaceutica; y su uso para el tratamiento de trastornos del metabolismo de lipidos, hiperlipidemia, resistencia a la insulina, diabetes y trastornos del snc, entre otras enfermedades.
CL2007002841A1 (es)	2008-02-08	Compuestos derivados de indol, antagonistas del receptor de glucagion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar diabetes mellitus tipo 2, hiperglucemia, diabetes o resistencia a la insulina.
CL2008001126A1 (es)	2008-10-24	Compuestos derivados de pirimidinona condensada con heterociclos; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, sindrome metabolico y obesidad.
CL2007002866A1 (es)	2008-07-04	Compuestos derivados de 6-sustituidos-2-(bencimidazolil) purina y purinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de enfermedades autoinmunes, enfermedad inflamatoria, enfermedad mediada por m
CL2008000531A1 (es)	2008-09-22	Compuestos derivados de heterociclos, inhibidores de la aspartilproteasa; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de enfermedades cardiovasculares, cognitivas y neurodegenerativas tales como la enfermeda
CL2007002996A1 (es)	2008-06-13	Compuestos derivados de quinolina sustituido, moduladores de los receptores x del higado; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como sindrome coronario agudo, alzheimer, diabetes y aterosclerosis.
CL2007003797A1 (es)	2008-07-18	Compuestos derivados de pirrolo piridina; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la enfermedad de alzheimer, parkinson, cancer, entre otras enfermedades.
CL2007001042A1 (es)	2008-02-08	Compuestos derivados de tioxantina; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento de desordenes neuroinflamatorios como esclerosis multiple, parkinson, en desordenes ateroscleroticos, cardio- y cerebrovascular, des
CL2007002641A1 (es)	2008-06-20	Compuestos derivados de pirimidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos alergicos, autoinmunes, enfermedades inflamatorias.
CL2007002234A1 (es)	2008-06-13	Compuestos derivados de heterociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades proliferativas.